Annual Cash & Cash Equivalents
$135.12 M
+$24.02 M+21.62%
December 31, 2023
Summary
- As of February 7, 2025, ALT annual cash & cash equivalents is $135.12 million, with the most recent change of +$24.02 million (+21.62%) on December 31, 2023.
- During the last 3 years, ALT annual cash & cash equivalents has risen by +$19.20 million (+16.56%).
- ALT annual cash & cash equivalents is now -29.00% below its all-time high of $190.30 million, reached on December 31, 2021.
Performance
ALT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$31.47 M
-$25.65 M-44.91%
September 30, 2024
Summary
- As of February 7, 2025, ALT quarterly cash and cash equivalents is $31.47 million, with the most recent change of -$25.65 million (-44.91%) on September 30, 2024.
- Over the past year, ALT quarterly cash and cash equivalents has dropped by -$103.64 million (-76.71%).
- ALT quarterly cash and cash equivalents is now -83.46% below its all-time high of $190.30 million, reached on December 31, 2021.
Performance
ALT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ALT Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +21.6% | -76.7% |
| 3 y3 years | +16.6% | -82.0% |
| 5 y5 years | +300.7% | +186.8% |
ALT Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.0% | +21.6% | -83.5% | at low |
| 5 y | 5-year | -29.0% | +1407.5% | -83.5% | +251.2% |
| alltime | all time | -29.0% | +9563.6% | -83.5% | >+9999.0% |
Altimmune Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $31.47 M(-44.9%) |
| Jun 2024 | - | $57.13 M(-27.7%) |
| Mar 2024 | - | $78.98 M(-41.5%) |
| Dec 2023 | $135.12 M(+21.6%) | $135.12 M(+55.6%) |
| Sep 2023 | - | $86.86 M(-15.1%) |
| Jun 2023 | - | $102.35 M(-2.2%) |
| Mar 2023 | - | $104.69 M(-5.8%) |
| Dec 2022 | $111.10 M(-41.6%) | $111.10 M(-12.8%) |
| Sep 2022 | - | $127.47 M(-6.2%) |
| Jun 2022 | - | $135.86 M(-24.5%) |
| Mar 2022 | - | $179.95 M(-5.4%) |
| Dec 2021 | $190.30 M(+64.2%) | $190.30 M(+8.8%) |
| Sep 2021 | - | $174.86 M(+0.4%) |
| Jun 2021 | - | $174.10 M(+16.1%) |
| Mar 2021 | - | $149.93 M(+29.3%) |
| Dec 2020 | $115.92 M(+1193.3%) | $115.92 M(-19.2%) |
| Sep 2020 | - | $143.50 M(+121.6%) |
| Jun 2020 | - | $64.74 M(+474.2%) |
| Mar 2020 | - | $11.28 M(+25.8%) |
| Dec 2019 | $8.96 M(-73.4%) | $8.96 M(-18.3%) |
| Sep 2019 | - | $10.97 M(-73.7%) |
| Jun 2019 | - | $41.67 M(-5.9%) |
| Mar 2019 | - | $44.30 M(+31.4%) |
| Dec 2018 | $33.72 M(+284.5%) | $33.72 M(+323.4%) |
| Sep 2018 | - | $7.96 M(+90.9%) |
| Jun 2018 | - | $4.17 M(-8.5%) |
| Mar 2018 | - | $4.56 M(-48.0%) |
| Dec 2017 | $8.77 M(+204.9%) | $8.77 M(-48.8%) |
| Sep 2017 | - | $17.12 M(+104.6%) |
| Jun 2017 | - | $8.37 M(-47.0%) |
| Mar 2017 | - | $15.78 M(+448.7%) |
| Dec 2016 | $2.88 M(-81.5%) | $2.88 M(-95.8%) |
| Sep 2016 | - | $69.11 M(+198.4%) |
| Jun 2016 | - | $23.16 M(+62.7%) |
| Mar 2016 | - | $14.24 M(-8.6%) |
| Dec 2015 | $15.57 M | $15.57 M(-10.5%) |
| Sep 2015 | - | $17.39 M(-5.6%) |
| Jun 2015 | - | $18.41 M(+17.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $15.72 M(-15.7%) |
| Dec 2014 | $18.64 M(+77.9%) | $18.64 M(-5.0%) |
| Sep 2014 | - | $19.62 M(+74.2%) |
| Jun 2014 | - | $11.27 M(+18.1%) |
| Mar 2014 | - | $9.53 M(-9.0%) |
| Dec 2013 | $10.48 M(-17.5%) | $10.48 M(-34.3%) |
| Sep 2013 | - | $15.94 M(+1.0%) |
| Jun 2013 | - | $15.79 M(+22.7%) |
| Mar 2013 | - | $12.87 M(+1.4%) |
| Dec 2012 | $12.70 M(+13.0%) | $12.70 M(-13.7%) |
| Sep 2012 | - | $14.73 M(+25.0%) |
| Jun 2012 | - | $11.78 M(-23.0%) |
| Mar 2012 | - | $15.30 M(+36.2%) |
| Dec 2011 | $11.24 M(-4.7%) | $11.24 M(+8.0%) |
| Sep 2011 | - | $10.41 M(-26.5%) |
| Jun 2011 | - | $14.16 M(+45.9%) |
| Mar 2011 | - | $9.71 M(-17.6%) |
| Dec 2010 | $11.79 M(+340.8%) | $11.79 M(+333.6%) |
| Sep 2010 | - | $2.72 M(+298.5%) |
| Jun 2010 | - | $682.00 K(-7.2%) |
| Mar 2010 | - | $735.10 K(-72.5%) |
| Dec 2009 | $2.67 M(-86.5%) | $2.67 M(-36.2%) |
| Sep 2009 | - | $4.19 M(-54.8%) |
| Jun 2009 | - | $9.27 M(-46.2%) |
| Mar 2009 | - | $17.25 M(-12.7%) |
| Dec 2008 | $19.75 M(-51.3%) | $19.75 M(+94.8%) |
| Sep 2008 | - | $10.14 M(-28.3%) |
| Jun 2008 | - | $14.15 M(-26.4%) |
| Mar 2008 | - | $19.24 M(-52.6%) |
| Dec 2007 | $40.58 M(+693.8%) | $40.58 M(-32.7%) |
| Sep 2007 | - | $60.34 M(>+9900.0%) |
| Mar 2007 | - | $467.40 K(-90.9%) |
| Dec 2006 | $5.11 M(+265.6%) | $5.11 M(+569.2%) |
| Sep 2006 | - | $763.90 K(-23.8%) |
| Jun 2006 | - | $1.00 M(-24.2%) |
| Mar 2006 | - | $1.32 M(-5.4%) |
| Dec 2005 | $1.40 M | $1.40 M(-5.0%) |
| Sep 2005 | - | $1.47 M(>+9900.0%) |
| Jun 2005 | - | $5800.00 |
FAQ
- What is Altimmune annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Altimmune?
- What is Altimmune annual cash & cash equivalents year-on-year change?
- What is Altimmune quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Altimmune?
- What is Altimmune quarterly cash and cash equivalents year-on-year change?
What is Altimmune annual cash & cash equivalents?
The current annual cash & cash equivalents of ALT is $135.12 M
What is the all time high annual cash & cash equivalents for Altimmune?
Altimmune all-time high annual cash & cash equivalents is $190.30 M
What is Altimmune annual cash & cash equivalents year-on-year change?
Over the past year, ALT annual cash & cash equivalents has changed by +$24.02 M (+21.62%)
What is Altimmune quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ALT is $31.47 M
What is the all time high quarterly cash and cash equivalents for Altimmune?
Altimmune all-time high quarterly cash and cash equivalents is $190.30 M
What is Altimmune quarterly cash and cash equivalents year-on-year change?
Over the past year, ALT quarterly cash and cash equivalents has changed by -$103.64 M (-76.71%)